Recurrent Mantle Cell Lymphoma Active Not Recruiting Phase 2 Trials for Rituximab (DB00073)

Also known as: Mantle Cell Lymphoma Recurrent

IndicationStatusPhase
DBCOND0028615 (Recurrent Mantle Cell Lymphoma)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01267812Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell TransplantationTreatment